HOUSTON, Texas, United States, March 2025 — PCCA, a leading FDA-registered supplier of active pharmaceutical ingredients, excipients, and consulting for the compounding industry, has announced the appointment of Gus Bassani, PharmD, as Chief Executive Officer of its U.S. business unit, effective April 1, 2025. A long-serving company veteran, Bassani brings extensive scientific leadership and a deep commitment to advancing personalized medicine.
Bassani joined PCCA in 2002 and most recently served as the company’s Chief Scientific Officer, where he led research and development, clinical services, and formulation development teams. He has also been highly active in business development, public affairs, and regulatory efforts within the compounding pharmacy sector.
Former CEO David L. Sparks will transition into the role of Chairman of the Board, while former President Jim Smith will become Executive Advisor to the Board of Directors. Both leaders will continue to provide strategic direction and governance across PCCA and its affiliated companies.
“Having the privilege to serve as PCCA’s president for 16 years is an honor I’ll always cherish,” said Jim Smith. “Gus is a gifted leader who has been an integral part of PCCA’s innovation, growth, and success. His deep understanding of our industry, coupled with his experience as a pharmacist and his groundbreaking approach to compounding pharmacy, makes him the ideal CEO to guide PCCA into the future.”
Bassani emphasized PCCA’s ongoing mission to support compounding pharmacies with high-quality products, clinical research, and consultative services, while strengthening quality systems, supply chain resilience, and pioneering new innovations.
“I am honored to take on this new role, alongside our dynamic and talented team at PCCA,” said Bassani. “Service to pharmacies in community and hospital settings and the safety and care of the patients they serve will always be the cornerstone of our mission.”
Looking to the future, Bassani highlighted the vital role of compounding pharmacists in advancing personalized medicine, integrating pharmacogenomics, automation, and cutting-edge formulation technologies. He also pointed to the need for expanded research and strategic investment in drug delivery innovations.
Before joining PCCA as a consultant pharmacist, Bassani worked as a formulation pharmacist and practiced in various pharmacy settings across Alaska, Iowa, and Kansas. He also taught extemporaneous compounding at Drake University, where he earned his Doctor of Pharmacy degree.
He has served multiple terms on the United States Pharmacopeia (USP) Compounding Expert Committee and is a member of key professional organizations including the Alliance for Pharmacy Compounding (APC), American Pharmacists Association (APhA), and National Community Pharmacists Association (NCPA).
About PCCA
Founded in 1981, PCCA supports the creation of personalized medicine and innovative products that improve patient outcomes. As a complete resource for independent compounding pharmacies and health systems, PCCA provides high-quality ingredients, education, and expert support to more than 3,000 pharmacy members across the United States, Canada, Australia, and other countries.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
